What's new
Fantasy Football - Footballguys Forums

This is a sample guest message. Register a free account today to become a member! Once signed in, you'll be able to participate on this site by adding your own topics and posts, as well as connect with other members through your own private inbox!

Stock Thread (23 Viewers)

What's the best free charting website for stocks?  I'm using yahoo finance at the moment but I can't figure out how to add the  8 month SMA and EMA.

I can add the 50 day and 200 day SMA but can't figure out how to add the EMA or the 8 month average.

 
Steeler said:
What's the best free charting website for stocks?  I'm using yahoo finance at the moment but I can't figure out how to add the  8 month SMA and EMA.

I can add the 50 day and 200 day SMA but can't figure out how to add the EMA or the 8 month average.
Click to expand...
If you have a TD Ameritrade account the thinkorswim platform likely has what you are looking for & more. Otherwise I have used koyfin in the past - has a decent interface. 

 
On the plus side, the press release today did contain some positive statements from Novant Health.    This is bullish

“We’re grateful for our partnership with CytoDyn and the opportunity to bring cutting edge, innovative and investigative treatments to our community,” said Eric Eskioglu, M.D. Executive Vice President and Chief Medical Officer for Novant Health. “Since initiating the leronlimab mild/moderate last month, Novant Health has screened nearly 400 patients for eligibility.  A number of these patients have been enrolled and treated on the mild/moderate clinical trial.  Expanding treatment options for our more critically ill patients is a vital step in our fight against COVID-19. We are encouraged by early reports of efficacy of leronlimab from critically ill patients treated under an Emergency Use IND and we are eagerly awaiting the full results of both blinded studies for leronlimab in the near future from CytoDyn.” 

 
Last edited by a moderator:
Jefferson the Caregiver said:
I don't want to get in a lot of arguments on this, maybe its semantics, but if your file contains mock datasets, why say the application is completed.

At the end of the day it won't matter if lebronlimade is the real deal but still questioning all the weird stuff at the current moment
Click to expand...
There has been weird stuff from the get go.  FOMO kept me in it.  Gonna take my couple/few grand whatever profit and walk away tomorrow.

Maybe the stock takes off, dunno.  Good on y'all if so.

 
Last edited by a moderator:
ghostguy123 said:
So they filed, but have to ammend some things.  What's the problem?

Did they lie when they said they competed a filing?  I mean, they filed right?  It is common or unheard of to have to refile because something wasnt fulfilled in the filing?  I have no idea.
Click to expand...
Its one thing to not have filed it at all and another to have filed and be advised by the FDA that additional data was needed to supplement the original filing. This type of thing happens frequently when dealing with regulatory agencies. As a newer investor in CYDY I believe that the BLA is a first for the company and you make more mistakes the first time you do something.

If the case is that the company filed nothing at all then I would be greatly alarmed and would probably dump it. But my preliminary impression is that its an easy fix. My additional impression is that the company is under a great deal of scrutiny and any misstep or delay is being pounced on to discredit it. Must be a lot at stake.

 
Last edited by a moderator:
Sharing a stock I am long on and have had good results with — AAXN.  Used to be Taser. 

Like them because:

— Primary growth in cameras and cloud data storage

— Have the best product on the market

— Law enforcement budgets tend to be stable and politically unwise to cut them

— Lots of barriers to exit for an agency that wants to switch to a different platform

— Expanding market to adjacent agencies outside policing, and also internationally.

— Nee management comp is highly incentivized on stock 

It was up 13% today after earnings announcement, but it feels like there is room to run.  Just a guy on an Internet board, but it has been good to me. 

 
eaganwildcats said:
It's mostly A) trying to seemingly sneak it in this PR does seem slightly fishy and B) the language is weird. Why not just say something like: "the FDA has requested additional clinical data as part of our previously filed BLA - that data will be provided on May 11th." Messing around with the 'completed' designation is just weird. 
Click to expand...
On the CytoDyn website they have a press release  from May 4th Release.  This press release contains:

 "We would like to provide an update that the Biologics License Application (BLA) for Leronlimab as a Combination Therapy for Highly Treatment Experienced HIV Patients will be considered completed after the clinical datasets are submitted on May 11, 2020. The clinical datasets are updated to address FDA comments for mock datasets from March 12 and March 20, 2020."

This same language was included in the Novant press release today.  I don't think they were trying to sneak this by.

Seems like they submitted to the FDA when they said, FDA made some comments, and they will update the filing on May 11 to address the comments.

 
needanap said:
On the CytoDyn website they have a press release  from May 4th Release.  This press release contains:

 "We would like to provide an update that the Biologics License Application (BLA) for Leronlimab as a Combination Therapy for Highly Treatment Experienced HIV Patients will be considered completed after the clinical datasets are submitted on May 11, 2020. The clinical datasets are updated to address FDA comments for mock datasets from March 12 and March 20, 2020."

This same language was included in the Novant press release today.  I don't think they were trying to sneak this by.

Seems like they submitted to the FDA when they said, FDA made some comments, and they will update the filing on May 11 to address the comments.
Click to expand...
Good find - hadn't noticed that. 

Pivoting because I don't want to be all CYDY all the time, but I think the weak hands are being shook out on Tankers - been listening to the earnings calls and getting all bulled up. Feeling good about some positive price action soon + dividends. 

 
The word "mock" is the one Im having the most issue with because that just means incomplete or not real to me.

I think there is a difference between the FDA saying you also need to include this document, rather than replacing your mock dataset with the clinical data.  The latter means it was never complete to begin with.

Maybe Im off here but that's how i read it

 
Last edited by a moderator:
Jefferson the Caregiver said:
The word "mock" is the one Im having the most issue with because that just means incomplete or not real to me.

I think there is a difference between the FDA saying you also need to include this document, rather than replacing your mock dataset with the clinical data.  The latter means it was never complete to begin with.

Maybe Im off here but that's how i read it
Click to expand...
Again no idea. Maybe adding "mock data" just gives the FDA a headstart to start reviewing since it's a time consuming processs. 

 
I think Adam Foreskin should be played by Paul Giamatti in Leronlimab: The Motion Picture.  Aziz Ansari as Dr Yo.  Are we going with Richard Pryor as Nader?  I was thinking Ricardo Montelban or Sir Ben Kingsley but it's hard to argue with Richard Pryor as the selection.

 
Don Hutson said:
I think Adam Foreskin should be played by Paul Giamatti in Leronlimab: The Motion Picture.  Aziz Ansari as Dr Yo.  Are we going with Richard Pryor as Nader?  I was thinking Ricardo Montelban or Sir Ben Kingsley but it's hard to argue with Richard Pryor as the selection.
Click to expand...
Montelban is dead so if you use him, you'll have to incorporate some weekend at Bernie's theme.

 
Another missed opportunity by CYDY.  Their BLA submission was rolling and changes were expected yet last night's PR implied they misled people and made a mistake.  Not the case but still more ammo for the shorts when it's actually good news.  #notselling

 
Don Hutson said:
I think Adam Foreskin should be played by Paul Giamatti in Leronlimab: The Motion Picture.  Aziz Ansari as Dr Yo.  Are we going with Richard Pryor as Nader?  I was thinking Ricardo Montelban or Sir Ben Kingsley but it's hard to argue with Richard Pryor as the selection.
Click to expand...
Who plays the guy who convinced his ifriends to buy and profit?

 
chet said:
Another missed opportunity by CYDY.  Their BLA submission was rolling and changes were expected yet last night's PR implied they misled people and made a mistake.  Not the case but still more ammo for the shorts when it's actually good news.  #notselling
Click to expand...
What you call a missed opportunity, I call a profit opportunity.

 
McBokonon said:
Link

VANCOUVER, Washington and WINSTON-SALEM, N.C., May 07, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that Novant Health is initiating patient enrollment in CytoDyn’s Phase 2b/3 trial for severely and critically ill COVID-19 patients.

Leronlimab has been administered to 54 severely and critically ill COVID-19 patients thus far under Emergency Investigational New Drug (EINDs) authorizations granted by the U.S. Food and Drug Administration (FDA).  Preliminary results from this patient population led to the FDA’s recent clearance for CytoDyn’s Phase 2b/3 clinical trial for 390 patients, which is randomized, placebo-controlled with 2:1 ratio (active drug to placebo ratio). Patients enrolled in this trial are expected to be administered leronlimab for two weeks with the primary endpoint being the mortality rate at 28 days and a secondary endpoint of mortality rate at 14 days. The Company will perform an interim analysis on the data from 50 patients.

“We’re grateful for our partnership with CytoDyn and the opportunity to bring cutting edge, innovative and investigative treatments to our community,” said Eric Eskioglu, M.D. Executive Vice President and Chief Medical Officer for Novant Health. “Since initiating the leronlimab mild/moderate last month, Novant Health has screened nearly 400 patients for eligibility.  A number of these patients have been enrolled and treated on the mild/moderate clinical trial.  Expanding treatment options for our more critically ill patients is a vital step in our fight against COVID-19. We are encouraged by early reports of efficacy of leronlimab from critically ill patients treated under an Emergency Use IND and we are eagerly awaiting the full results of both blinded studies for leronlimab in the near future from CytoDyn.” 

Nader Pourhassan, Ph.D., President and Chief Executive Officer of CytoDyn, added, “We are once again very pleased Novant Health is seeking to partner with our health care professionals to help provide a potential therapeutic benefit to these COVID-19 patients.  Thus far, we are grateful for the benefits leronlimab has provided to so many patients, as expressed to us by their families.”
Click to expand...
Novant seems to be a pretty major deal in the Carolinas and other parts of Southeast.
Click to expand...
it is and you can damn well be sure that I'll be telling anyone I know diagnosed with COVID to go to a Novant hospital if the poop hits the fan because they will have the juice that prevents a dirt nap.  We have three major healthcare systems in the area and they are very competitive.

 
SHAREHOLDER ALERT: Investigation of CytoDyn Announced by Holzer & Holzer, LLC

May 08, 2020 07:30 AM Eastern Daylight Time

https://www.businesswire.com/news/home/20200508005109/en/

ATLANTA--(BUSINESS WIRE)--Holzer & Holzer, LLC is investigating whether CytoDyn Inc. (“CytoDyn” or the “Company”) (OTC: CYDY) complied with federal securities laws. On April 27, 2020, CytoDyn issued a press release indicating it had submitted a “completed Biologics License Application (BLA) to the FDA for Leronlimab as a Combination Therapy for Highly Treatment Experienced HIV Patients.” On May 7, 2020, CytoDyn announced that its BLA for Leronlimab “will be considered completed after the clinical datasets are submitted on May 11, 2020.”

If you purchased shares of CytoDyn and suffered a loss on that investment, you are encouraged to contact Marshall P. Dees, Esq. at mdees@holzerlaw.com or Luke R. Kennedy at lkennedy@holzerlaw.com, or at www.holzerlaw.com to discuss your legal rights.

Holzer & Holzer, LLC is an Atlanta, Georgia law firm that dedicates its practice to vigorous representation of shareholders and investors in litigation nationwide, including shareholder class action and derivative litigation. Since its founding in 2000, Holzer & Holzer attorneys have played critical roles in recovering hundreds of millions of dollars for shareholders victimized by fraud and other corporate misconduct. More information about the firm is available through its website, www.holzerlaw.com and upon request from the firm. Holzer & Holzer, LLC has paid for the dissemination of this promotional communication, and Corey D. Holzer is the attorney responsible for its content.
Click to expand...

 
Steeler said:
What's the best free charting website for stocks?  I'm using yahoo finance at the moment but I can't figure out how to add the  8 month SMA and EMA.

I can add the 50 day and 200 day SMA but can't figure out how to add the EMA or the 8 month average.
Click to expand...
I'm using yahoo as well. 

Upper left of the chart has "indicators", select "moving average", then in the upper left of the chart click the moving average box to change it to 8.

 
Jefferson the Caregiver said:
On the plus side, the press release today did contain some positive statements from Novant Health.    This is bullish

“We’re grateful for our partnership with CytoDyn and the opportunity to bring cutting edge, innovative and investigative treatments to our community,” said Eric Eskioglu, M.D. Executive Vice President and Chief Medical Officer for Novant Health. “Since initiating the leronlimab mild/moderate last month, Novant Health has screened nearly 400 patients for eligibility.  A number of these patients have been enrolled and treated on the mild/moderate clinical trial.  Expanding treatment options for our more critically ill patients is a vital step in our fight against COVID-19. We are encouraged by early reports of efficacy of leronlimab from critically ill patients treated under an Emergency Use IND and we are eagerly awaiting the full results of both blinded studies for leronlimab in the near future from CytoDyn.” 
Click to expand...
This is the thing for me... all of the hit pieces trying to derail the company are about SEC filing gaffs, insider trading (which sounds bad but an explanation was provided as to why), and other types of administrative stuff the CEO seems to fumble around.  They don't talk about contracts with production partners (Samsung, Aji Bio-Pharma) and other partners like Novant health.  

I haven't seen anything where AF or whoever has bashed the science behind leronlimab.  Just all shots at the CEO.  Could ND be better?  Yes.  I think he is passionate about the company and its flagship product. He needs admin help.  Help with PR.  Help with filings.  Have professionals review anything going out before release.  

But the science... if it saves lives, I hope this truth reaches decision-makers and, more importantly, reaches patients (and their families) in desperate need of treatment.   To think that people are paid money to write hit pieces on these small companies that may have a product that could change the landscape of Covid treatment and save lives is despicable.  

 
Damn, those guys just fly out of the woodwork. I laughed because there are some of those on one stock I own that is now at all time highs. Some period were it went down but it’s ambulance chasing at its finest. Unless we are talking real fraud like those 100 shares of LK that I thought were a bargain at $24, these still show up on stocks with no reason seeing as how all stocks go up and down and most all have good and bad earnings occasionally.

 
Jayrok said:
This is the thing for me... all of the hit pieces trying to derail the company are about SEC filing gaffs, insider trading (which sounds bad but an explanation was provided as to why), and other types of administrative stuff the CEO seems to fumble around.  They don't talk about contracts with production partners (Samsung, Aji Bio-Pharma) and other partners like Novant health.  

I haven't seen anything where AF or whoever has bashed the science behind leronlimab.  Just all shots at the CEO.  Could ND be better?  Yes.  I think he is passionate about the company and its flagship product. He needs admin help.  Help with PR.  Help with filings.  Have professionals review anything going out before release.  

But the science... if it saves lives, I hope this truth reaches decision-makers and, more importantly, reaches patients (and their families) in desperate need of treatment.   To think that people are paid money to write hit pieces on these small companies that may have a product that could change the landscape of Covid treatment and save lives is despicable.  
Click to expand...
Agreed, but that’s what OTC stocks have happen and it’s not easy to take on opinion pieces. That said this is the guy who pumped and dumped Gilead with the good news followed by bad new leaks.

 
There likely will be more law firms too.  Saw this happen with a hit piece against a stock I own and the legal portion just extends the news cycle.  

 
Whether valid or not all of this hurts a company trying to enroll patients in trials, something that we know has not been easy to do so far.

Going to need some help from the FDA and the medical community soon to provide some good news.

 
chet said:
Decent choice but a little old.  I was thinking either of the two leads from Once Upon a Time in Hollywood.   :lol:   
Click to expand...
Go with Pitt.  Don't want people thinking you're Jordan Belfort pushing pinks.  

 
Last edited by a moderator:
I have no choice but to make my scheduled buy today. I prefer doing it when the market was down, but that didn’t happen this week.

nonetheless, feels like A TON of optimism is baked in right now. Like an insane amount.

 
Lots of permabears limping back into the market lately with their tails between their legs despite being 100% sure "we haven't hit bottom yet!" , "we're about to crash!", etc. Very good sign for the market. 

At some point, they need to admit they completely missed the falling knife and were out during the quickest bounceback in history and they won't get another chance. Very good lesson for next time there's a sharp bear market down the line. 

Nobody in particular. There are a ton in this thread that repeat "its about to drop, I'm sure of it this time" over and over for weeks, hoping to eventually be right. Perhaps not this time. 

In another note, CYDY taking a hit this morning. You guys adding more? 

 
In the spirit of this market, I'm looking for ways to invest in clocks running backwards, or lions whelping in the street.

 
Bought at 2.66 and 2.60, out at 2.93 all while shopping at Lowe’s.  I’ve done this enough now the cost basis for my shares may be negative. 

 
You must log in or register to reply here.

Similar threads

Andrew74
2025 FBG Stock Contest
2
Replies
77
Views
4K
Andrew74
Andrew74
Andrew74
2024 FBG Stock Contest
2 3
Replies
127
Views
7K
McBokonon
McBokonon
Joey Wright
2025-2026 NCAA College Basketball Thread
Replies
6
Views
196
SpurrierisisGod
SpurrierisisGod

Users who are viewing this thread

  • ... and 2 more.
    • Total: 23 (members: 8, guests: 15)
    Back
    Top